Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: A discrete event simulation model

Clinical Nutrition

Volumn 33, Issue 5, 2014, Pages 785-792

  Pradelli, Lorenzo ^a   Eandi, Mario ^b   Povero, Massimiliano ^a   Mayer, Konstantin ^c   Muscaritoli, Maurizio ^d   Heller, Axel R ^e   Fries Schaffner, Eva ^f  

^a AdRes HE and OR   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f Fresenius Kabi Deutschland GmbH   (Germany)

Author keywords

Cost; Model; Nutrition; Omega 3; Parenteral; Pharmacoeconomics

Indexed keywords

ANTIBIOTIC AGENT; OMEGA 3 FATTY ACID;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DRUG COST; FRANCE; GERMANY; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION RATE; INTENSIVE CARE UNIT; ITALY; LENGTH OF STAY; MORTALITY; PARENTERAL NUTRITION; SIMULATION; THERAPY EFFECT; TREATMENT OUTCOME; UNITED KINGDOM; COST BENEFIT ANALYSIS; CROSS INFECTION; ECONOMICS; EUROPE; HOSPITAL; HOSPITAL COST; HOSPITALIZATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; CROSS INFECTION; DIETARY SUPPLEMENTS; EUROPE; FATTY ACIDS, OMEGA-3; FRANCE; GERMANY; GREAT BRITAIN; HOSPITAL COSTS; HOSPITALIZATION; HOSPITALS; HUMANS; INTENSIVE CARE UNITS; ITALY; LENGTH OF STAY; MODELS, ECONOMIC; PARENTERAL NUTRITION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 84906054990     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.11.016     Document Type: Article

References (23)

1. Pradelli L., Mayer K., Muscaritoli M., Heller A.R. n-3 fatty acid-enriched parenteral nutrition regimens in elective surgical and ICU patients: a meta-analysis. Crit Care 2012, 16(5):R184.
2. Badía-Tahull M.B., Llop-Talaverón J.M., Leiva-Badosa E., Biondo S., Farran-Teixidó L., Ramón-Torrell J.M., et al. Arandomised study on the clinical progress of high-risk elective major gastrointestinal surgery patients treated with olive oil-based parenteral nutrition with or without a fish oil supplement. Br J Nutr 2010, 104(5):737-741.
3. Jiang Z.M., Wilmore D.W., Wang X.R., Wei J.M., Zhang Z.T., Gu Z.Y., et al. Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br J Surg 2010, 97(6):804-809.
4. Kłek S., Kulig J., Szczepanik A.M., Jedrys J., Kołodziejczyk P. The clinical value of parenteral immunonutrition in surgical patients. Acta Chir Belg 2005, 105(2):175-179.
5. Liang Bin, Wang Shan, Ye Ying-Jiang, Yang Xiao-Dong, Wang You-Li, Qu Jun, et al. Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients. World J Gastroenterol 2008, 14(15):2434-2439.
6. Makay O., Kaya T., Firat O., Sozbilen M., Caliskan C., Gezer G., et al. ω-3 Fatty acids have no impact on serum lactate levels after major gastric cancer surgery. JParenter Enteral Nutr 2011, 35(4):488-492.
7. Mertes N., Grimm H., Fürst P., Stehle P. Safety and efficacy of a new parenteral lipid emulsion (SMOFlipid) in surgical patients: a randomized, double-blind, multicenter study. Ann Nutr Metab 2006, 50(3):253-259.
8. Progetto MARGHERITA - Rapporto 2009 Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva (GIVITI) 2010, Sestante Edizioni, Bergamo.
9. Tarricone R., Torbika A., Franzetti F., Rosenthal V.D. Hospital costs of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of intensive care units in Italy. Cost Eff Resour Alloc 2010, 8:8.
10. Agenzia Nazionale per I Servizi Sanitari Regionali Ricoveri, Personale e spesa delle Aziende Ospedaliere (2003). http://www.assr.it/agenas_pdf/2_Ricoveri_personale_e_spesa_aziende_ospedaliere_(2003).pdf.
11. Orsi G.B., Di Stefano L., Noah N. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs. Infect Control Hosp Epidemiol 2002, 23(4):190-197.
12. Garrigues B. Etude CRRéa: evaluation médico-économique du CoÛt Réel d'une journée en RÉAnimation Décembre 2010, Séminaire ENC 2, Available at:, [Last accessed June 2012]. http://www.snmrhp.org/Data/ModuleGestionDeContenu/application/880.pdf.
13. Martin J., Neurohr C., Bauer M., Weiss M., Schleppers A. Kosten der intensivmedizinischen Versorgung in einem deutschen Krankenhaus. Anaesthesist 2008, 57:505-512.
14. Bennet D., Bion J. Organisation of intensive care. BMJ 1999, 318:1468-1470.
15. Agence Régionale de l'Hospitalisation. Report 2009.
16. Statistisches Bundesamt Gesundheit, Grunddaten der Krankenhäuser 2012, Report.
17. Department of Health NHS Institute for Innovation and Improvement 2009, Report.
18. Brun-Buisson C., Roudot-Thoraval F., Girou E., Grenier-Seeelier C., Durand-Zaleski I. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 2003, 29:1464-1471.
19. Moerer O., Schmid A., Hofmann M., Herklotz A., Reinhart K., Werdan K., et al. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 2002, 28:1440-1446.
20. Plowman R., Graves N., Griffin M.A.S., Roberts J.A., Swan A.V., Cookson B., et al. The rate and cost of hospital acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. JHosp Infect 2001, 47:198-220.
21. Chen B., Zhou Y., Yang P., Wan H.W., Wu X.T. Safety and efficacy of fish oil-enriched parenteral nutrition regimen on postoperative patients undergoing major abdominal surgery: a meta-analysis of randomized controlled trials. JParenter Enteral Nutr 2010, 34(4):387-394.
22. Buxton M.J., Drummond M.F., Van Hout B.A., Prince R.L., Sheldon T.A., Szucs T., et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997, 6:217-227.
23. Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care?. Eur J Health Econ 2003, 4:143-150.